PubMed Health⌕ Search

Biomedical subjects

R E Lind

Publications and source records attributed to R E Lind.

4 recordsLinked to original sources
PubMed1998

Cyclic hydroxamic acid inhibitors of prostate cancer cell growth: selectivity and structure activity relationships.

BACKGROUND: Clinical symptoms of prostatitis, prostatodynia, and benign prostatic hyperplasia are relieved by the pollen extract cernilton, and the water-soluble fraction of this extract selectively inhibits growth of some prostate cancer cells. A cyclic hydroxamic acid, DIBOA, has been isolated from this extract and mimics its cell growth-inhibitory properties, but the specificity of DIBOA for inhibition of prostate cell growth has not been reported. METHODS: The in vitro growth inhibitory effects of DIBOA and nine structurally related compounds on DU-145 prostate cancer cells, MCF-7 breast cancer cells, and COS-7 monkey kidney cells were determined by treatment of the cells with various concentrations of the compounds for 2-6 days. RESULTS: The compounds exhibited a wide range of potencies, but none of them exhibited selective inhibition of DU-145 cell growth. MCF-7 cells were more sensitive to DIBOA than either DU-145 cells or COS-7 cells. 3,4-dihydroquinoline-2(1H)-one, compound (4), and 1-hydroxy-6-chloro-3,4-dihydroquinolin-2(1H)-one, compound (7), selectively inhibited MCF-7 cell growth at a concentration of 10 micrograms/ml. 1-hydroxy-3,4-dihydroquinolin-2(1H)-one, compound (3), and compound 7 were the most potent inhibitors of DU-145 cell growth. Treatment of DU-145 cells with 3 (100 micrograms/ml) substantially decreased the number of viable cells within 2 days, and no viable cells remained in the culture by day 4. CONCLUSIONS: It is unlikely that DIBOA, compound (1), is responsible for the selective growth inhibition of prostate cancer cells by the water-soluble fraction of the pollen extract cernilton. Cell morphology results indicate that the growth-inhibitory effects of DIBOA and structurally related agents on DU-145 cells are due to their ability to cause cell death.

Benzoxazines↗
PubMed1982

Aortofemoral bypass grafting: Microvel.

One hundred seventy-five patients underwent elective aortofemoral bypass during the years from 1976 to 1979. One hundred eighteen of these patients received a knitted double velour prosthesis (Microvel) and the remainder received standard knitted Dacron. All patients had been followed for a minimum of 12 months. Early graft thrombosis occurred in three limbs, and these were restored by reoperation for 100 per cent patency at discharge from the hospital. The operative mortality was three patients (1.7%). Complications included myocardial infarction (three/one death), renal failure (one/one death), respiratory failure (one/one death), cerebrovascular accident (four), and superficial wound infection (five). Late complications were infrequent, but included seven graft limb occlusions in six patients (3.4%), and one graft infection, one ureteral obstruction, and one false aneurysm. Among the 256 symptomatic extremities, claudication was completely relieved in 199 (78%) and substantially improved in an additional 48 (18.5%). Hemodynamic assessment with arm/ankle or arm/high thigh indices improved in parallel with symptomatic relief. Thus, only nine (3.5%) symptomatic extremities failed to improve with the proximal reconstruction, requiring distal reconstruction or amputation. The authors remain advocates of aortofemoral grafting with end-to-end proximal anastomosis and hooding of the distal anastomosis over the profunda origin for most aortoiliac occlusive diseases. Our recent experience with double velour graft and this technique have been very satisfactory.

Adult↗
PubMed1976

Lactational response of dairy cows to oral administration of a synthetic glucocorticoid.

Effects of oral administration of 0, 5, 10, or 20 mug of 6 alpha, 9 alpha-difluoro-16alpha-methyl-prednisolone (Flumethasone) daily on milk and milk component yields, udder health reproductive performance, and body weight change were measured. With 24 Holstein cows in a randomized block design, daily Flumethasone administration was initiated 4 days postpartum and continued until milk secretion ceased or the completion of 305 days on treatment. Mature equivalent yields (adjusted for days open) of milk, solids-not-fat, and milk fat were higher for cows receiving 5 or 10 mug Flumethasone than for cows receiving 0 or 20 mug Flumethasone daily. Lactations for cows receiving 20 mug Flumethasone were 37 to 48 days shorter than lactations for cows in other treatment groups. There were no differences between treatment groups for measures of udder health, reproductive efficiency, and body weight changes. A second experiment of 45 Holstein cows in their second or third lactations included treatments 0, 5, or 10 mug Flumethasone daily for 25 days followed by a 5 day withdrawal. Treatments were begun between day 210 and day 270 of lactation. During the 30 days, Flumethasone failed to alter milk production. These experiments indicate that Flumethasone given continuously increased milk components and milk yield but had no significant effect on milk yield when given only during the latter stage of lactation.

Animals↗